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Abstract: In this pilot study, we wished to determine if C-reactive protein (CRP) levels could be a useful
severity or treatment biomarker for canine atopic dermatitis (AD). Nine atopic dogs received allergen
immunotherapy for 1 year. Blood was collected before and at four re-evaluation visits. At each time point,
the skin lesions were graded with the Canine Atopic Dermatitis Extent and Severity Index (CADESI)
4, and the plasma CRP levels were measured by Enzyme-linked Immunosorbent Assay (ELISA). We
found a significant yet minimal correlation between the CRP levels and the CADESI4 scores. The CRP
levels were not significantly different between dogs with AD of increasing severity. Finally, there was
no correlation between the percentage change in CADESI4 and CRP values during immunotherapy. In
conclusion, the lack of significant difference in CRP levels between dogs of increasing AD severity and
lack of correlation between percentage changes in skin lesion and CRP values suggest that this protein
would not be a clinically-useful biomarker in atopic dogs.
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Evaluierung des C-reaktiven Proteins 
als Biomarker im Plasma bei Hun-
den mit atopischer Dermatitis unter 
 allergenspezifischer Immuntherapie: 
Eine Pilotstudie
Das Ziel der vorliegenden Studie war es, C-reaktives 
Protein (CRP) im Plasma zu bestimmen und als Biomar-
ker für Schweregrad und Behandlung der atopischen 
Dermatitis bei Hunden (AD) zu evaluieren. Neun ato-
pische Hunde erhielten während eines Jahres eine 
allergenspezifische Immuntherapie. Vor Therapiebeginn 
und bei vier Nachuntersuchungen wurden jeweils die 
Hautläsionen mit dem «Canine Atopic Dermatitis Ex-
tent and Severity Index» (CADESI) 4 bewertet und den 
Tieren Blut entnommen. Die Plasma CRP-Spiegel wur-
den mittels Enzyme-linked Immunosorbent Assay (ELI-
SA) gemessen. Wir fanden eine minimale signifikante 
Korrelation zwischen den CRP- und CADESI4-Werten. 
Die CRP-Werte unterschieden sich nicht signifikant 
zwischen den Hunden mit unterschiedlicher AD Schwe-
re. Es konnte keine Korrelation zwischen der Prozentu-
alen Veränderung der CADESI4- und CRP-Werte wäh-
rend der Immuntherapie festgestellt werden. 
Zusammenfassend, das Fehlen eines signifikanten Un-
terschiedes zwischen den CRP-Werten bei Hunden mit 
unterschiedlichen AD-Schweregrade und das Fehlen 
einer Korrelation zwischen den prozentualen Hautläsi-
onsveränderungen und den CRP-Werten zeigen, dass 
dieses Protein kein klinisch nützlicher Biomarker bei 
atopischen Hunden ist.
Schlüsselwörter: Neurodermitis, Biomarker, CRP, Hund
Abstract
In this pilot study, we wished to determine if C-reactive 
protein (CRP) levels could be a useful severity or treat-
ment biomarker for canine atopic dermatitis (AD). Nine 
atopic dogs received allergen immunotherapy for 1 year. 
Blood was collected before and at four re-evaluation 
visits. At each time point, the skin lesions were graded 
with the Canine Atopic Dermatitis Extent and Severity 
Index (CADESI) 4, and the plasma CRP levels were 
measured by Enzyme-linked Immunosorbent Assay 
(ELISA). We found a significant yet minimal correlation 
between the CRP levels and the CADESI4 scores. The 
CRP levels were not significantly different between dogs 
with AD of increasing severity. Finally, there was no 
correlation between the percentage change in CADESI4 
and CRP values during immunotherapy. In conclusion, 
the lack of significant difference in CRP levels between 
dogs of increasing AD severity and lack of correlation 
between percentage changes in skin lesion and CRP 
values suggest that this protein would not be a clinical-
ly-useful biomarker in atopic dogs.
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details on the enrolled dogs, their CADESI4 and corre-
sponding CRP plasma levels are presented in the Table 
1. Altogether, we collected CADESI4 and CRP plasma 
level pairs from 43 dog-visits. General examination was 
carried at all time points and were unremarkable.
On nine occasions, the dogs had been receiving anti-al-
lergic drugs known to affect inflammation (cyclospo-
rine, oclacitinib, prednisolone, topical glucocorticoids); 
these visits are colored red in the Table 1 and in the two 
figures). No other treatments, except dewormers, had 
been administered during the study.
At baseline, the dogs’ CADESI4 skin lesion scores 
ranged from 20 to 60 (median: 24) and after intra-lym-
phatic (four dogs), subcutaneous (two dogs), and sub-
lingual AIT (three dogs) their final CADESI4 grades 
varied between 0 to 78 (median: 4). The corresponding 
CRP plasma levels varied between 0.1 and 12.9 µg/ml 
(median 1.6) when starting the AIT, and 0.2 and 6.1 µg/
ml (median: 2.4) after one year of this intervention. Of 
note is that in only 2/9 atopic dogs (22%) were CRP 
plasma levels consistently above the upper threshold for 
healthy dogs with this assay (10 µg/ml) when their AD 
was active during the first months of AIT (values in blue 
in Table 1).
The correlation between the CADESI4 and CRP plasma 
levels was significant but weak (Figure 1; Spearman r = 
0.27; P = 0.040). After removal of the dogs concurrent-
ly treated with anti-allergic drugs, the correlation was 
Statistics
Statistical analyses were performed using Graphpad 8.0 
(GraphPad, La Jolla, California, USA). After determin-
ing that the CADESI4 and CRP values did not have a 
normal distribution, non-parametric analyses were 
used. The correlation between the CADESI4 and the 
CRP plasma levels was assessed using a one-tailed Spear-
man Rank correlation test using the single assumption 
that the correlation would be positive. Additionally, 
comparisons were made between the CRP plasma levels 
of dogs in groups of different CADESI4-based skin le-
sion severity, that is, in dogs with AD in remission 
(CADESI4 < 10), and those with mild (11-34), moder-
ate (35-59) and severe disease (> 59). For this, we used 
the Kruskal-Wallis test and repeated the two tests 
with two different subpopulations: 1) in dogs not treat-
ed with anti-allergic drugs, and 2) in dogs with active 
AD (i.e., after removal of the dogs with AD in remis-
sion). Finally, we assessed if there was a correlation 
between the percentage change in CADESI4 values (a 
proxy for treatment response) and those of plasma CRP 
levels.
Results
We included nine dogs in this study; seven of them had 
blood collected at the time of starting AIT and at four 
re-evaluation visits, while the other two missed a sched-
uled visit and had only three post-treatment samples; 
among others) that should induce a rise in CRP produc-
tion.6,11 Furthermore, canine AD skin is known to have 
a high expression of the CRP-inducing cytokine TNF-al-
pha.7,9,10 Therefore, we wished to determine if this acute-
phase protein could be used as a biomarker of disease 
severity or immunotherapy efficacy in dogs with AD.
Materials and methods
The collection of blood samples in this study was ap-
proved beforehand by our institution’s Animal Care and 
Use Committee.
Atopic dogs
Client-owned dogs with AD presented to the University 
of Zurich Small Animal Internal Medicine Clinic were 
selected. In these dogs, the diagnosis of AD was made 
based on a compatible history, characteristic clinical 
signs and the exclusion of resembling pruritic dermato-
ses (e.g. ectoparasitoses, yeast, and bacterial infections, 
and so on) using standard methods.3,4  
All dogs had been treated with allergen immunotherapy 
(AIT) as part of another study during which they were 
bled on five separate occasions: at the initiation of AIT 
and at re-evaluation visits scheduled at approximately 
1, 3, 6 and 12 months after beginning this intervention. 
The present study was consequently retrospective. The 
blood was centrifuged, and the plasma was isolated and 
stored at -80°C until used. At each visit, the extent and 
severity of AD skin lesions were assessed using the 
CADESI4, a complete general examination was carried 
out and all anti-allergic medications (e.g., cyclosporine, 
oclacitinib, prednisolone, topical glucocorticoids)—as 
well as those used for other problems—taken in the last 
two weeks were also recorded.12 
Plasma CRP levels
The CRP plasma levels were measured using the TECO 
canine CRP ELISA (TECO medical, Sissach, Switzer-
land) by the Laboratoire Cerba (Saint-Ouen-l’Aumône, 
France). This assay has reported inter- and intra-assay 
coefficients of variations lower than 5% and a limit of 
detection of 30 ng/ml; the proposed cut-off value in 
healthy dogs is 10 µg/ml; this cut-off value is similar to 
that proposed in a recent paper.15
Introduction
To assess the severity of skin lesions of canine atopic 
dermatitis (AD) for mechanistic studies or during clin-
ical trials, lesion severity scales, such as one of the Ca-
nine Atopic Dermatitis Extent and Severity Index 
(CADESI) iterations or the Canine Atopic Dermatitis 
Lesion Index (CADLI) often are used.12,14 Despite yield-
ing a score that, at first, might appear as representing an 
objective measure of skin lesion severity, these time-con-
suming instruments only reflect the aggregation of sub-
jectively-graded individual or grouped skin lesions on 
the entire body surface or at specific body sites.
To remedy the inherent subjectivity of clinician-assessed 
skin lesion scales, the search for more “objective” bio-
markers of disease severity or treatment response in 
humans with AD has been ongoing for decades.5 Com-
monly used biomarkers for human AD include histo-
logical lesions or immunostains from collected skin 
biopsies, or the serum levels of specific cytokines, 
chemokines or inflammation-associated proteins.5 One 
such biomarker is the C-reactive protein (CRP), a liv-
er-originating acute-phase protein whose blood levels 
increase during inflammation, including that which 
occurs during inflammatory skin diseases including AD, 
psoriasis and contact dermatitis.17,20 First reported to 
parallel the response to antihistamine therapy in hu-
mans with AD in 2015, serum CRP levels were recently 
shown to positively correlate with both the skin lesion 
scores and the affected body surface area in human pa-
tients with moderate-to-severe AD.8,19 In veterinary 
dermatology, the CRP serum level recently was found a 
valid disease severity biomarker for canine pemphigus 
foliaceus.15
To date, there is only one publication that reports a 
useful biomarker for canine AD.2 In this paper, a spe-
cific ELISA was developed for the canine S100A8 (cal-
granulin A, one of the two calprotectin subunits), and 
serum levels of S100A8 rose with increasing levels of 
AD severity in 213 atopic dogs.2 Furthermore, the cor-
relation between the CADESI3 values and the S100A8 
serum levels was 85% and highly significant.2 Unfortu-
nately, there is no validated commercially-available En-
zyme-linked Immunosorbent Assay (ELISA) that would 
permit the use of such biomarker in veterinary derma-
tology research and practice.
At the time of this writing, we could only identify one 
study that reported, in abstract form, that CRP serum 
levels (assessed by latex coagulating nephelometry) were 
not elevated in canine AD.16 This finding is surprising 
in light of the observation that acute allergen challeng-
es in sensitized dogs lead to a rapid increase in the ex-
pression of pro-inflammatory cytokines (e.g., IL-6 
Table 1: Characteristics, Canine Atopic Dermatitis Extent and Severity Index 4 (CADESI4) and C-reactive protein (CRP) plasma levels of dogs (n=9) invol-
ved in a pilot study on atopic dermatitis (AD). Results of animals with allergen-specific immunotherapy a shown in red and without treatment in black. 
Supplementary Material 1: characteristics of study subjects, CADESI4 and CRP plasma levels
Initial after 1 month after 3 months after 6 months after 12 months Change during 
AIT
AIT Breed Age (yrs) Sex CADESI4 CRP  
(μg/ml)
CADESI4 CRP  
(μg/ml)
CADESI4 CRP  
(μg/ml)
CADESI4 CRP  
(μg/ml) 
CADESI4 CRP  
(μg/ml)
CADESI4 CRP
ILIT Labrador 6.9 FS 24 1.6 2 8.9 7 3.1 0 12.4 0 1.5 –100% –6%
ILIT  West Highland 
white terrier
8.7 MC 54 0.2 28 0.7 13 0.6 4 0.7 11 NC –80% –
ILIT crossbred 2.5 FS 23 1.2 6 4.1 7 0.8 4 1.2 4 2.1 –83% +75%
ILIT Boston terrier 2.8 FS 20 0.1 0 0.0 0 0.0 4 0.4 0 0.2 –100% +100%
SCIT  French bulldog 5.1 FS 60 10.4 36 2.0 13 4.9 12 14.4 0 2.6 2.6 –100% –75%
SCIT  Jack Russell 
terrier
4.4 FS 52 7.8 5 15.4 5 15.6 23 1.5 7 4.5 –87% –42%
SCIT Boxer 8.0 MI 23 6.3 12 0.4 9 ND 9 1.7 3 3.3 –87% –48%
SLIT boxer 2.0 MC 30 12.9 41 46.0 158 62.7 20 0.9 78 6.1 +160% –53%
SLIT  West Highland  
white terrier
2.0 FS 20 0.6 5 0.0 4 1.8 2 0.6 10 1.6 –50% +167%
Abbreviations: AIT: allergen immunotherapy; FS: female spayed; ILIT: intralymphatic immunotherapy; M: male; MC: male castrated; NC: not collected; 
SCIT: subcutaneous Immunotherapy; SLIT:
sublingual immunotherapy
 red text: treated with anti-allergic drugs
 blue text: CRP values above the upper limit for healthy dogs (i.e., 10 μg/ml)
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Our results are consistent with those of the abstract re-
porting that CRP levels were not raised in canine AD, 
even though details were not provided on the number 
of dogs assessed and whether or not they were receiving 
treatment. Nevertheless, from the information con-
tained in that abstract, one can infer that all dogs with 
AD had CRP values in the range of those of healthy 
dogs (i.e., up to 0.1 mg/dl = 10 µg/ml).18 One should 
also keep in mind that these values are low when com-
pared to those of dogs with inflammatory gastro-intes-
tinal disease, such as inflammatory bowel disease or 
pancreatitis.13,21
Of interest is that the range of CRP plasma levels in our 
seven dogs with moderate-to-severe AD was identical 
to that determined in the serum of human atopic pa-
tients with a disease of similar severity (0.02 to 6.2 mg/
dl = 0.2-62.0 µg/ml).19 While only 39% of human pa-
tients with moderate-to-severe AD had a CRP serum 
level superior to the upper reference range for humans 
(0.5 mg/dl = 5.0 µg/ml), 5/7  (71%) of our dogs with 
the same severity had plasma levels above that thresh-
old. 19 However, only 2/9 atopic dogs (22%) would have 
CRP plasma levels above the cut-off for healthy dogs 
using this assay (i.e., 10 µg/ml), a threshold twice that 
of humans. 
Conclusion:
In summary, the results of our pilot study established a 
weak correlation between CRP levels and the CADESI4 
scores. However, the lack of separation of CRP levels 
between dogs of increasing AD severity, and the absence 
of correlation between the percentage change in atopic 
skin lesion and those of CRP values suggest that the 
CRP plasma levels would unlikely form a valid severity 
and treatment biomarker for canine AD. 
Acknowledgments: 
The authors thank Franco Martini for the assembling 
of canine plasma samples and Vanessa Chala and Sofia 
Loukeri from Virbac SA for their sponsoring of the CRP 
plasma level measurements.
slightly stronger (Spearman r = 0.36; P = 0.026). The 
correlation was highest when we compared the values 
of dogs with active AD, that is after removing those with 
scores of disease remission (Spearman r = 0.44; P = 
0.027).
We then grouped the CRP plasma levels based on the 
canine AD severity category of their corresponding 
CADESI4 (Figure 2).12 The CRP levels were not signifi-
cantly different between AD severity groups (Krus-
kal-Wallis test, P = 0.169). When removing the values 
from dogs treated with anti-allergic drugs or those from 
dogs with AD in remission, the values were not signifi-
cantly different between groups, either. 
Finally, we compared the percentage change in CADE-
SI4 values with those of CRP plasma levels during AIT 
in eight dogs. While the percentage change in skin lesion 
scores suggested a strong improvement of AD in 7/8 
dogs (88%) after treatment with AIT (median: -87%; 
range: -100 to +160%), there was no such corresponding 
change in CRP plasma levels (median: -24%; range: -75 
to +167%). The percentage change in CADESI4 and 
CRP values were not significantly correlated (Spearman 
r = 0.13; P = 0.744).
Discussion
A biomarker is a parameter that is objectively measured 
and evaluated as an indicator of normal biological or 
pathogenic processes, or pharmacologic responses to 
treatment.1 Biomarkers can be used as a tool for diag-
nosis, for predicting the severity of a disease, as an in-
dicator for disease prognosis or to monitor the clinical 
response to an intervention.1
We could not find a set of criteria that defines the char-
acteristics of a useful biomarker for canine AD. Never-
theless, one could envision that such a biomarker should 
allow the separation of dogs with a controlled AD from 
those with an active disease, as well as distinguish be-
tween dogs of increasing disease severity categories; its 
values should also strongly correlate with skin lesion 
scores graded with validated instruments and the evo-
lution of this biomarker should mirror that of skin le-
sions during treatment.
In spite of the limitation of having followed only a small 
number of dogs — albeit having done so over one year 
with 43 value pairs — we found that the CADESI4 skin 
lesion scores were correlated significantly with the CRP 
plasma levels, but this positive correlation was minimal. 
Even when only considering dogs with active AD or 
those untreated with anti-allergic drugs, the correlation 
remained weak at best. Importantly, when segregating 
the dogs among CADESI-based categories of increasing 
AD severity, there was no significant difference in CRP 
plasma levels. Altogether, these observations suggest that 
CRP plasma levels cannot serve as a useful biomarker 
for the severity of canine AD. That the percentage 
change in CADESI4 scores and those of the CRP plasma 
levels during AIT were not correlated suggest that the 
CRP might not be a useful treatment biomarker either. 
Figure 1: Correlation between Canine Atopic Dermatitis Ex-
tent and Severity Index 4 (CADESI4) and C-reactive protein 
(CRP) plasma levels in untreated (black dots) and with an-
ti-allergic drugs treated (red dots) dogs with canine atopic 
dermatitis at the time of blood collection. Spearmann test 
showed a low correlation (r = 0,27, P  = 0.04), which was in-
creased (r = 0,36, P = 0.02) when treated dogs were removed 
(red dots). 
Evaluierung des C-reaktiven Proteins 
als Biomarker im Plasma bei Hunden 
mit atopischer Dermatitis unter aller-
genspezifischer Immuntherapie: Eine 
Pilotstudie
Das Ziel der vorliegenden Studie war es, C-reaktives 
Protein (CRP) im Plasma zu bestimmen und als Biomar-
ker für Schweregrad und Behandlung der atopischen 
Dermatitis bei Hunden (AD) zu evaluieren. Neun ato-
pische Hunde erhielten während eines Jahres eine 
allergenspezifische Immuntherapie. Vor Therapiebeginn 
und bei vier Nachuntersuchungen wurden jeweils die 
Hautläsionen mit dem «Canine Atopic Dermatitis Ex-
tent and Severity Index» (CADESI) 4 bewertet und den 
Tieren Blut entnommen. Die Plasma CRP-Spiegel wur-
den mittels Enzyme-linked Immunosorbent Assay (ELI-
SA) gemessen. Wir fanden eine minimale signifikante 
Korrelation zwischen den CRP- und CADESI4-Werten. 
Die CRP-Werte unterschieden sich nicht signifikant 
zwischen den Hunden mit unterschiedlicher AD Schwe-
re. Es konnte keine Korrelation zwischen der Prozentu-
alen Veränderung der CADESI4- und CRP-Werte wäh-
rend der Immuntherapie festgestellt werden. 
Zusammenfassend, das Fehlen eines signifikanten Un-
terschiedes zwischen den CRP-Werten bei Hunden mit 
unterschiedlichen AD-Schweregrade und das Fehlen 
einer Korrelation zwischen den prozentualen Hautläsi-
onsveränderungen und den CRP-Werten zeigen, dass 
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unterschiedlichen AD-Schweregrade und das Fehlen 
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onsveränderungen und den CRP-Werten zeigen, dass 
Figure 2: C-reactive protein (CRP) plasma levels in dogs with 
increasing Canine Atopic Dermatitis Extent and Severity 
Index 4 (CADESI4) based on Atopic dermatitis (AD) severity 
categories. Dogs treated with anti-allergic drugs at the time 
of blood collection are shown in red. Bars represent me-
dians. CRP levels were not significantly different between 
severity groups (Kruskal-Wallis ANOVA, P = 0.169)
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dieses Protein kein klinisch nützlicher Biomarker bei 
atopischen Hunden ist.
Mots clés: Coxciella burnetii, avortement, mortalité périnatale, 
chèvre, zoonose
dieses Protein kein klinisch nützlicher Biomarker bei 
atopischen Hunden ist.
Parole chiave: Coxiella burnetii, aborto, nati morti, capra, 
zoonosi
